StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Halozyme Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 35.9%. For fiscal 2025 it was 33.6%, against 54.3% the year before. The highest annual figure on record is 62.2% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202533.6%−20.7
FY2024Dec 31, 202454.3%+13.6
FY2023Dec 31, 202340.7%+0.2
FY2022Dec 31, 202240.5%−21.7
FY2021Dec 31, 202162.2%+8.3
FY2020Dec 31, 202053.9%+88.4
FY2019Dec 31, 2019-34.5%+11.2
FY2018Dec 31, 2018-45.7%−71.2
FY2017Dec 31, 201725.6%+82.3
FY2016Dec 31, 2016-56.7%−36.4
FY2015Dec 31, 2015-20.3%+63.3
FY2014Dec 31, 2014-83.7%+63.1
FY2013Dec 31, 2013-146.8%−20.1
FY2012Dec 31, 2012-126.7%−91.3
FY2011Dec 31, 2011-35.4%+362.9
FY2010Dec 31, 2010-398.2%+29.4
FY2009Dec 31, 2009-427.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202659.8%−2.3
Q1 FY2026Mar 31, 202649.0%−4.5
Q4 FY2025Dec 31, 2025-20.6%−79.5
Q3 FY2025Sep 30, 202561.5%+5.3
Q2 FY2025Jun 30, 202562.2%+11.5
Q1 FY2025Mar 31, 202553.4%+4.7
Q4 FY2024Dec 31, 202458.9%+15.0
Q3 FY2024Sep 30, 202456.3%+15.4
Q2 FY2024Jun 30, 202450.7%+7.9
Q1 FY2024Mar 31, 202448.8%+15.6
Q4 FY2023Dec 31, 202343.9%+2.9
Q3 FY2023Sep 30, 202340.9%+1.0
Q2 FY2023Jun 30, 202342.7%+20.4
Q1 FY2023Mar 31, 202333.2%−31.3
Q4 FY2022Dec 31, 202241.1%−14.4
Q3 FY2022Sep 30, 202239.9%−25.4
Q2 FY2022Jun 30, 202222.4%−45.8
Q1 FY2022Mar 31, 202264.5%+7.5
Q4 FY2021Dec 31, 202155.4%−8.4
Q3 FY2021Sep 30, 202165.3%+3.6
Q2 FY2021Jun 30, 202168.2%+14.7
Q1 FY2021Mar 31, 202157.0%+69.7
Q4 FY2020Dec 31, 202063.8%+123.5
Q3 FY2020Sep 30, 202061.7%+114.8
Q2 FY2020Jun 30, 202053.5%+89.2
Q1 FY2020Mar 31, 2020-12.7%−17.9
Q4 FY2019Dec 31, 2019-59.7%−59.6
Q3 FY2019Sep 30, 2019-53.1%+46.6
Q2 FY2019Jun 30, 2019-35.7%+21.3
Q1 FY2019Mar 31, 20195.2%+82.0
Q4 FY2018Dec 31, 2018-0.1%−66.5
Q3 FY2018Sep 30, 2018-99.7%−112.4
Q2 FY2018Jun 30, 2018-57.0%+18.5
Q1 FY2018Mar 31, 2018-76.8%+16.3
Q4 FY2017Dec 31, 201766.4%+124.3
Q3 FY2017Sep 30, 201712.7%+84.1
Q2 FY2017Jun 30, 2017-75.5%–
Q1 FY2017Mar 31, 2017-93.1%–
Q4 FY2016Dec 31, 2016-57.9%–
Q3 FY2016Sep 30, 2016-71.4%–

More Halozyme Therapeutics figures

See a number that looks wrong?